37WWW.CEN-ONLINE.ORG DECEMBER 20, 2010

THREE YEARS AGO, the National Re-search Council released the report “Toxic-ity Testing in the 21st Century,” calling for the development of new approaches to human health risk assessment that would rely on in vitro assays and computer-based models instead of animal testing.

Although the scientific community has embraced the NRC vision, many scientists worry that the transition will be too slow. The Human Toxicology Project Consor-tium—a coalition of corporations, the Hamner Institutes for Health Sciences, and the Humane Society of the U.S.—convened a meeting last month to take a snapshot of the current scientific landscape and dis-cuss how to accelerate the transformation of toxicology into a science that is both predictive and compassionate.

But before scientists can understand how a chemical will behave in a living sys-tem simply by running it through a panel of cell-based screening assays or plugging

it into a computational model, they need a clear understanding of the cellular path-ways that are involved in toxicity and the responses that are indicative of adverse outcomes. At last month’s meeting, partici-pants learned about a number of ongoing initiatives, in the U.S. and around the world, to identify those pathways and use them to develop new approaches to toxicology.

For example, in the U.S., several gov-ernment agencies, including the National Institutes of Health, the Environmental Protection Agency, and the Food & Drug Administration, are collaborating on a project called Tox21 to “research, develop, validate, and translate innovative chemical

testing methods that characterize toxicity pathways,” said Ray-mond Tice, chief of the biomolecular screening branch at the National Toxicology Program at the National Insti-tute of Environmental Health Sciences.

A significant con-tribution to the Tox21 effort comes from ToxCast, an EPA program that builds predictive toxicology models with data from

high-throughput screening assays, said Robert J. Kavlock, director of EPA’s Na-tional Center for Computational Toxicol-ogy. In the first phase of the program, more than 300 compounds, mostly pesticides, were analyzed. The second phase is cur-rently under way, with the goal of analyzing an additional 700 compounds, including failed drugs donated by pharmaceutical companies, Kavlock said.

Whereas U.S. efforts are science-driven, the search for alternative methods of toxic-ity testing is policy-driven in the European Union, said Horst Spielmann, a professor of regulatory toxicology at Free University of Berlin and retired head of the National German Center for the Documentation & Evaluation of Alternatives to Testing in Animals at the Federal Institute for Risk Assessment. REACH (Registration, Evalua-tion, Authorization & Restriction of Chemi-cal substances) is a European Commission law that requires industry to provide safety information about chemicals (C&EN, Nov. 29, page 15), and under the Cosmetics Directive, another European law, the cos-metics industry must eliminate the use of animals in toxicity testing by 2013.

SCIENCE & TECHNOLOGY

CHANGING APPROACHES New methods could make it easier to assess the safety of new compounds.

CE

NT

ER

FO

R A

LTE

RN

AT

IVE

S T

O A

NIM

AL

TE

ST

ING

“The paradigm shift in toxicology that is about to happen is a once-

in-a-lifetime opportunity.”

TRANSFORMING TOXICOLOGY

Consortium works to ACCELERATE DEVELOPMENT of 21st-century toxicology

CELIA HENRY ARNAUD , C&EN WASHINGTON

38WWW.CEN-ONLINE.ORG DECEMBER 20, 2010

The EC’s Joint Research Centre in Ispra, Italy, is providing scientific support to help implement those policies, said Maurice Whelan, head of the systems toxicology unit of the Institute for Health & Con-sumer Protection at JRC. Whelan’s team is selecting appropriate chemicals, assays, and cell systems to build and evaluate in vitro models of toxicity. For example, the group is culturing neurons on microchips to monitor neuronal electrophysiology as a type of in vitro EEG, a medical test of brain electrical activity. The reliability of this neurotoxicity test system was demonstrat-ed recently in a round-robin trial involving six labs in Europe and the U.S.

Several European nongovernmental programs are also helping steer the devel-opment of new approaches to toxicology. AXLR8, an EU project coordinated by Spielmann, seeks to accelerate the transi-tion to a toxicity-pathway-based paradigm for chemical safety assessment by provid-ing a forum for networking, information exchange, and collaboration, Spielmann said. The Transatlantic Think Tank of Toxicology is an effort—shared among the Center for Alternatives to Animal Testing (CAAT) at Johns Hopkins University; the University of Konstanz, in Germany; and Utrecht University, in the Netherlands—that seeks to advance evidence-based toxicology, said Thomas Hartung, director of CAAT.

MUCH OF THE FOCUS has been on iden-tifying chemicals that pose hazards to hu-man health, but risk assessment requires exposure information as well. The Risk Assessment in the 21st Century Project (Risk21)—sponsored by the ILSI Health & Environmental Sciences Institute, part of the International Life Sciences Institute—is trying to look at the whole picture. In Risk21, approximately 90 scientists from industry, academia, government, and non-governmental organizations participate on four project teams that are focusing on ways to characterize real-world chemi-cal exposure, incorporate dose-response information into risk assessment, develop a framework for toxicity testing, and ac-count for the cumulative risk of exposure to multiple agents, said Timothy P. Pastoor, a toxicologist at Syngenta who is cochair of Risk21.

In addition to projects undertaken by government and nongovernmental organizations, companies are launching programs to advance predictive toxicology.

For example, U.K.-based Unilever’s skin sensitization program is devel-oping in vitro and computational methods to assess the risk of contact dermatitis, said Cameron MacKay, a mathematical modeler in the toxicol-ogy modeling group at Unilever’s Safety & Environmental Assurance Centre. To do this, MacKay and his colleagues are work-ing to understand the biology of allergic responses in human skin and incorporating what they learn into computational models of the process.

With so many different projects contrib-uting to the implementation of the NRC vision for 21st-century toxicity testing, there’s a need to coordinate the various ef-forts, said Martin Stephens, vice president for animal research issues at the Humane Society. The Human Toxicology Project Consortium is calling for an international large-scale program analogous to the Hu-man Genome Project that can “get us to the finish line sooner rather than later,” Stephens said. Such a “human toxicol-ogy project” would underscore a sense of mission and urgency, he said. It is espe-cially important that any data be publicly available.

The many projects already under way are potential partners for such an en-deavor, said Andrew N. Rowan, chief sci-entific officer at the Humane Society. Each

SCIENCE & TECHNOLOGY

leading the world to advanced

electrochemical technologies

Potentiostat/GalvanostatsMultichannel Potentiostats

Single Cell and Array Fuel CellsElectrochemical Process Control

Electrode FabricationCombinatorial Electrochemistry

Short CoursesRapid Prototyping

www.nuvant.com(866) 894-7337(219) 644-3231

TOXICITY TESTS Researchers at the Institute for Health & Consumer Protection use microelectrode arrays, as seen on the computer screens, for cell-based “in vitro EEGs.”

EU

RO

PE

AN

UN

ION

39WWW.CEN-ONLINE.ORG DECEMBER 20, 2010

individual project may be small, but col-lectively more than $200 million annually is already being spent on the various pro-grams, Rowan said. Thus, resources are not the issue. What is needed is coordination.

Part of the consortium’s work is in developing a pilot project to gauge the ef-fectiveness of pathway-based approaches to toxicity testing, said Melvin E. Andersen, director of the Program in Chemical Safety Sciences at the Hamner Institutes. For this project, consortium members are selecting a group of no more than 10 well-studied compounds and pathways, which they incorporate into assays using human or rodent cells or tissue surrogates. They will then use the results from those assays to refine quantitative risk assessment.

George P. Daston, a toxicologist at Procter & Gamble, worries that a headlong rush to find a replacement for the current toxicology paradigm will simply replace an existing “one size fits all” system of default methods with another. People don’t yet know what will work, he said. He urges the community not to be too hasty in trying to nail down a particular set of pathways and assays. “All these approaches need to be integrated,” he said.

Such caution notwithstanding, meet-ing participants were optimistic about the prospects for modernizing toxicology. “The paradigm shift in toxicology that is about to happen is a once-in-a-lifetime opportunity,” Hartung said. Paraphrasing Victor Hugo, Hartung noted that “noth-ing is as strong as an idea whose time has come.” ■

Reaxys ® is a registered trademark owned and protected by Elsevier Properties SA and used under license

Reaxys fuels discovery and innovation by

integrating reaction and substance data

search with synthesis planning.

Does your work flow?

Easy access to relevant,

actionable results means

chemists can move more

quickly through the steps

in their workflow and deliver

superior outcomes.

• Experimentally validated reaction

and substance data

• Tools to evaluate hit sets and design

synthesis strategies

• An intuitive interface designed

by chemists for chemists

reaxys.com